Phaos Technology Holdings (Cayman) (POAS) Common Equity (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) posted Common Equity of -$3.5 million for Q4 2025, down 12559.76% on a QoQ basis from $27867.6 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Common Equity (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman)'s Common Equity history runs 2 years deep, the most recent figure standing at -$3.5 million for Q4 2025.

Quarterly Common Equity changed N/A year-over-year to -$3.5 million in Q4 2025, while the trailing twelve-month figure through Oct 2025 was -$3.5 million (changed N/A YoY) and the FY2025 annual result came in at -$2.0 million, down 7196.66% from the prior year.
Common Equity was -$3.5 million for Q4 2025 at Phaos Technology Holdings (Cayman), down from $27867.6 in the prior quarter.
Across five years, Common Equity topped out at $27867.6 in Q2 2025 and bottomed at -$3.5 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Abbott Laboratories	183.97 Bn	176.68 Bn	6.27 Bn	52.70 Bn
2	Stryker	128.89 Bn	126.01 Bn	3.81 Bn	38.00 Mn
3	Medtronic	108.90 Bn	99.68 Bn	6.41 Bn	50.07 Bn
4	Boston Scientific	68.64 Bn	67.19 Bn	3.61 Bn	25.86 Bn
5	Edwards Lifesciences	48.32 Bn	44.65 Bn	1.29 Bn	10.33 Bn
6	Dexcom	28.44 Bn	27.32 Bn	750.30 Mn	2.96 Bn
7	GE HealthCare Technologies	28.37 Bn	26.09 Bn	1.98 Bn	10.67 Bn
8	Smith & Nephew	27.00 Bn	26.42 Bn	-	5.29 Bn
9	Koninklijke Philips	25.84 Bn	22.71 Bn	2.07 Bn	13.34 Bn
10	Phaos Technology Holdings (Cayman)	6.24 Mn	6.18 Mn	-	-3.47 Mn

Download Data